Screening of two-photon activated photodynamic therapy sensitizers using a 3D osteosarcoma model.
Antineoplastic Agents
/ pharmacology
Benzylidene Compounds
/ pharmacology
Cell Line, Tumor
Cell Survival
/ drug effects
Cisplatin
/ pharmacology
Eosine Yellowish-(YS)
/ pharmacology
Humans
Mesenchymal Stem Cells
Osteosarcoma
/ drug therapy
Photons
Photosensitizing Agents
/ pharmacology
Porphyrins
/ pharmacology
Journal
The Analyst
ISSN: 1364-5528
Titre abrégé: Analyst
Pays: England
ID NLM: 0372652
Informations de publication
Date de publication:
07 May 2019
07 May 2019
Historique:
pubmed:
28
3
2019
medline:
6
7
2019
entrez:
28
3
2019
Statut:
ppublish
Résumé
Photodynamic therapy (PDT) involves a photosensitizing agent activated with light to induce cell death. Two-photon excited PDT (TPE-PDT) offers numerous benefits compared to traditional one-photon induced PDT, including an increased penetration depth and precision. However, the in vitro profiling and comparison of two-photon photosensitizers (PS) are still troublesome. Herein, we report the development of an in vitro screening platform of TPE-PS using a 3D osteosarcoma cell culture. The platform was tested using three different two-photon (2P) active compounds - a 2P sensitizer P2CK, a fluorescent dye Eosin Y, and a porphyrin derivative (TPP). Their 2P absorption cross-sections (σ
Substances chimiques
Antineoplastic Agents
0
Benzylidene Compounds
0
Photosensitizing Agents
0
Porphyrins
0
5,10,15,20-tetra(4-hydroxyphenyl)porphyrin
51094-17-8
Cisplatin
Q20Q21Q62J
Eosine Yellowish-(YS)
TDQ283MPCW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM